It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AVGO’s FA Score shows that 3 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AVGO’s TA Score shows that 4 TA indicator(s) are bullish while NVAX’s TA Score has 3 bullish TA indicator(s).
AVGO (@Semiconductors) experienced а -2.62% price change this week, while NVAX (@Biotechnology) price change was +4.87% for the same time period.
The average weekly price growth across all stocks in the @Semiconductors industry was -7.19%. For the same industry, the average monthly price growth was +1.30%, and the average quarterly price growth was -15.72%.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.71%. For the same industry, the average monthly price growth was +3.67%, and the average quarterly price growth was -3.87%.
AVGO is expected to report earnings on Dec 05, 2024.
NVAX is expected to report earnings on Nov 06, 2024.
The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.
@Biotechnology (-2.71% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
AVGO | NVAX | AVGO / NVAX | |
Capitalization | 638B | 1.86B | 34,264% |
EBITDA | 20.4B | -228.25M | -8,937% |
Gain YTD | 48.125 | 149.062 | 32% |
P/E Ratio | 110.93 | N/A | - |
Revenue | 42.6B | 560M | 7,607% |
Total Cash | N/A | 1.05B | - |
Total Debt | 74B | 233M | 31,760% |
AVGO | NVAX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | 95 | |
SMR RATING 1..100 | 42 | 100 | |
PRICE GROWTH RATING 1..100 | 3 | 41 | |
P/E GROWTH RATING 1..100 | 8 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AVGO's Valuation (61) in the Semiconductors industry is in the same range as NVAX (88) in the Biotechnology industry. This means that AVGO’s stock grew similarly to NVAX’s over the last 12 months.
AVGO's Profit vs Risk Rating (4) in the Semiconductors industry is significantly better than the same rating for NVAX (95) in the Biotechnology industry. This means that AVGO’s stock grew significantly faster than NVAX’s over the last 12 months.
AVGO's SMR Rating (42) in the Semiconductors industry is somewhat better than the same rating for NVAX (100) in the Biotechnology industry. This means that AVGO’s stock grew somewhat faster than NVAX’s over the last 12 months.
AVGO's Price Growth Rating (3) in the Semiconductors industry is somewhat better than the same rating for NVAX (41) in the Biotechnology industry. This means that AVGO’s stock grew somewhat faster than NVAX’s over the last 12 months.
AVGO's P/E Growth Rating (8) in the Semiconductors industry is significantly better than the same rating for NVAX (100) in the Biotechnology industry. This means that AVGO’s stock grew significantly faster than NVAX’s over the last 12 months.
AVGO | NVAX | |
---|---|---|
RSI ODDS (%) | N/A | N/A |
Stochastic ODDS (%) | 3 days ago81% | 3 days ago79% |
Momentum ODDS (%) | 3 days ago41% | 3 days ago89% |
MACD ODDS (%) | 3 days ago44% | 3 days ago87% |
TrendWeek ODDS (%) | 3 days ago46% | 3 days ago84% |
TrendMonth ODDS (%) | 3 days ago82% | 3 days ago87% |
Advances ODDS (%) | 24 days ago80% | 5 days ago84% |
Declines ODDS (%) | 10 days ago49% | 11 days ago90% |
BollingerBands ODDS (%) | 3 days ago90% | 3 days ago87% |
Aroon ODDS (%) | 3 days ago79% | N/A |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SSSIX | 29.50 | N/A | N/A |
SouthernSun Small Cap, I | |||
IYIGX | 34.44 | -0.06 | -0.17% |
Delaware Ivy Global Growth Fund Class R | |||
BMPEX | 23.94 | -0.07 | -0.29% |
Beck Mack + Oliver Partners | |||
PRILX | 62.75 | -0.19 | -0.30% |
Parnassus Core Equity Institutional | |||
JORFX | 19.25 | -0.06 | -0.31% |
Janus Henderson Global Select I |
A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with ADMA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then ADMA could also see price increases.
Ticker / NAME | Correlation To NVAX | 1D Price Change % | ||
---|---|---|---|---|
NVAX | 100% | +0.72% | ||
ADMA - NVAX | 43% Loosely correlated | -0.77% | ||
ITOS - NVAX | 42% Loosely correlated | -4.68% | ||
THRD - NVAX | 42% Loosely correlated | -0.91% | ||
RXRX - NVAX | 35% Loosely correlated | +1.15% | ||
VIR - NVAX | 33% Loosely correlated | +0.72% | ||
More |